Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could ...

And Novo Nordisk (NYSE: NVO) stock, down 4.9%, is the victim. Where to invest $1,000 right now? Our analyst team just ...

Wealth host Brad Smith discusses some of Wednesday's trending stocks. Novo Nordisk (NVO) stock is sinking after European drugmaker Roche (ROG.SW) reached a deal with Zealand Pharma (ZEAL.CO) to ...

The private equity firms have emerged as the frontrunner after they teamed up and other potential bidders including Bain ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...